Clinical Trial Update: Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating budesonide delivered via a mucosal atomization device as a topical nasal spray for chronic rhinosinusitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis

Drugs mentioned

• Budesonide (BUDESONIDE)

Snippet

Sponsor: St. Paul's Hospital, Canada | Conditions: Chronic Rhinosinusitis | Phase 1, Phase 2 | Status: COMPLETED